1. American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Atlanta, GA: American Cancer Society; 2017.
2. Siegel R, Miller K, Jemal A. Cancer statistics, 2018. CA Cancer J Clin
3. PDQ Screening and Prevention Editorial Board. PDQ esophageal cancer screening. https://www.cancer.gov/types/esophageal/hp/esophagealscreening-pdq
. Updated February 22, 2019. Accessed August 6, 2019.
4. World Health Organization-International Agency for Research on Cancer. Global cancer data—Globocan 2018. https://www.uicc.org/news/global-cancer-data-globocan-2018#:~:text=GLOBOCAN%202018%20is%20an%20online,for%20all%20cancer%20sites%20combined
. Accessed January 13, 2021.
5. Thrift AP. The epidemic of the oesophageal carcinoma: where are we now? Cancer Epidemiol 2016;41:88–95.
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
7. Islami F. Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997–2014. Clin Gastroenterol Hepatol 2019;17:429–439.
8. Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol 2013;37:579–584.
9. Wang QL, Xie SH, Li WT, et al. Smoking cessation and risk of esophageal cancer by histological type: systematic review and meta-analysis. J Natl Cancer Inst 2017;109: doi: 10.1093/jnci/djx115.
10. Sun X, Elston R, Barnholtz-Sloan J, et al. A segregation analysis of
Barrett’s esophagus and associated adenocarcinomas. Cancer Epidemiol
Biomarkers Prev 2010;19:666–674.
11. Contini S, Scarpignato C. Caustic injury of the upper gastrointestinal tract: a comprehensive review. World J Gastroenterol 2013;19:3918–3930.
12. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998;90:1039–1071.
13. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 2008;(38):1–93.
14. Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am 2012;92:1077–1087.
15. Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal cancer. J Gastrointest Oncol 2012;3:226–231.
16. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with
Fanconi anemia. Blood 2003;101:822–826.
17. Velleuer E, Dietrich R. Fanconi anemia: young patients at high risk for squamous cell carcinoma. Mol Cell Pediatr 2014;1:9.
18. Ellis NA, German J. Molecular genetics of Bloom’s syndrome. Hum Mol Genet 1996;5(Spec No):1457–1463.
19. Petrick JL, Wyss AB, Butler AM, et al. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer 2014;110:2369–2377.
20. Islami F, Boffetta P, Ren JS, et al. High-temperature beverages and foods and esophageal cancer risk—a systematic review. Int J Cancer 2009;125:491–524.
21. Islami F, Ren JS, Taylor PR, et al. Pickled vegetables and the risk of oesophageal cancer: a meta-analysis. Br J Cancer 2009;101:1641–1647.
22. Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: a multicentre case-control study. Eur J Cancer 2012;48:655–661.
23. Steevens J, van den Brandt PA, Goldbohm RA, et al. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 2010;138:1704–1713.
24. Cross AJ, Freedman ND, Ren J, et al. Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol 2011;106:432–442.
25. Liu J, Wang J, Leng Y, et al. Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer 2013;133:473–485.
26. Chang-Claude J, Becher H, Blettner M, et al. Familial aggregation of oesophageal cancer in a high incidence area in China. Int J Epidemiol 1997;26:1159–1165.
27. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–1453.
28. Iwaya T, Maesawa C, Ogasawara S, et al. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. Gastroenterology 1998;114:1206–1210.
29. Sherman SK, Maxwell JE, Qian Q, et al. Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations. Cancer Genet 2015;208:41–46.
30. Sandler RS, Nyrén O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995;274:1359–1362.
31. Appelqvist P, Salmo M. Lye corrosion carcinoma of the esophagus: a review of 63 cases. Cancer 1980;45:2655–2658.
32. Ruol A, Rampado S, Parenti A, et al. Caustic ingestion and oesophageal
cancer: intra- and peri-tumoral fibrosis is associated with a better
prognosis. EurJ Cardiothorac Surg 2010;38:659–664.
33. Novacek G. Plummer-Vinson syndrome. Orphanet J Rare Dis 2006;1:36.
34. Chisholm M. The association between webs, iron and postcricoid carcinoma. Postgrad Med J 1974;50:215–219.
35. Itskoviz D, Tamary H, Krasnov T, et al. Endoscopic findings and esophageal cancer incidence among Fanconi anemia patients participating in an endoscopic surveillance program. Dig Liver Dis 2019;51:242–246.
36. Alter BP. Fanconi's anemia, transplantation, and cancer. Pediatr Transplant 2005;9(suppl 7):81–86.
37. Han Y, Chen W, Peiwei L, et al. Association between coeliac disease and risk of any malignancy and gastrointestinal malignancy. Medicine (Baltimore) 2015;94:e1612.
38. Bonifazi M, Tramacere I, Pomponio G, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology 2013;52:143–154.
39. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831.
40. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86–91.
41. Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 2010;138:1297–1301.
42. Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019;90:335–359.e2.
43. Chakraborty S, Iyer PG. Predictors of progression in Barrett’s esophagus. Curr Treat Options Gastroenterol 2019;17:18–31.
44. Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology 2018;154:1282–1289.e2.
45. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375–1383.
46. Desai TK, Krishnan K, Samala N. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012;61:970–976.
47. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706–1718.
48. Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst 2014;106:dju252.
49. Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011;60:1029–1037.
50. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012;142:442–452.e5.
51. Sun L, Yu S. Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma. Dis Esophagus 2011;24:544–549.
52. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and metaanalysis. Gastroenterology 2003;124:47–56.
53. Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010;139:73–83.
54. Rezaizadeh H, McCarty TR, Njei B, et al. Daily proton pump inhibitors are cost-effective in reducing Barrett’s induced esophageal adenocarcinoma mortality: 2016 ACG Presidential Poster Award. Am J Gastroenterol 2016;111:S211.
55. Sasaki Y, Tamura M, Koyama R, et al. Genomic characterization of esophageal squamous cell carcinoma: insights from next-generation sequencing. World J Gastroenterol 2016;22:2284–2293.
56. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 1995;109:1541–1546.
57. Paraf F, Fléjou JF, Pignon JP, et al. Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases. Am J Surg Pathol 1995;19:183–191.
58. Cavallin F, Scarpa M, Cagol M, et al. Esophageal cancer clinical presentation: trends in the last 3 decades in a large Italian series. Ann Surg 2018;267:99–104.
59. Fang TC, Oh YS, Szabo A, et al. Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer. Dis Esophagus 2016;29:642–648.
60. Graham DY, Schwartz JT, Cain GD, et al. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982;82:228–233.
61. Park J, Cho YK, Kim JH. Current and future use of esophageal capsule endoscopy. Clin Endosc 2018;51:317–322.
62. Keller J, Fibbe C, Volke F, et al. Remote magnetic control of a wireless
capsule endoscope in the esophagus is safe and feasible: results of a
randomized, clinical trial in healthy volunteers. Gastrointest Endosc
63. Oka A, Amano Y, Kusunoki R, et al. Superficial esophageal cancer observed with the PillCam ESO 2 in combination with the flexible spectral imaging color enhancement system. Dig Endosc 2011;23:195–196.
64. Yim S, Gultepe E, Gracias DH, et al. Biopsy using a magnetic capsule endoscope carrying, releasing, and retrieving untethered microgrippers. IEEE Trans Biomed Eng 2014;61:513–521.
65. Wang X, Kambhampati S, Cheng Y, et al. Methylation biomarker panel performance in EsophaCap cytology samples for diagnosing Barrett’s esophagus: a prospective validation study. Clin Cancer Res 2019;25:2127–2135.
66. Rusch VW, Appelman HD, Blackstone E, et al. Esophagus and esophagogastric junction. In AJCC Cancer Staging Manual, 7th ed. Chicago: AJCC; 2010:103–115.
67. Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008;14:1479–1490.
68. Catalano MF, Van Dam J, Sivak MVJr. Malignant esophageal strictures: staging accuracy of endoscopic ultrasonography. Gastrointest Endosc 1995;41:535–539.
69. Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997;112:1087–1095.
70. Sun F, Chen T, Han J, et al. Staging accuracy of endoscopic ultrasound for esophageal cancer after neoadjuvant chemotherapy: a meta-analysis and systematic review. Dis Esophagus 2015;28:757–771.
71. Overholt BF, Wang KK, Burdick JS, et al. International photodynamic group for high-grade dysplasia in Barrett’s esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc 2007;66:460–468.
72. Canto MI, Shaheen NJ, Almario JA, et al. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc 2018;88:438–446.e2.
73. Attwood SE, Lewis CJ, Caplin S, et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol 2003;1:258–263.
74. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011;141: 460–468.
75. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007;65:3–10.
76. Pouw RE, van Vilsteren FG, Peters FP, et al. Randomized trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic resection of early Barrett’s neoplasia. Gastrointest Endosc 2011;74:35–43.
77. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008;57:1200–1206.
78. Lewis JJ, Rubenstein JH, Singal AG, et al. Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett’s esophagus. Gastrointest Endosc 2011;74:753–760.
79. Ono S, Fujishiro M, Niimi K, et al. Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc 2009;70:860–866.
80. Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 2010;72:255–264.
81. Repici A, Hassan C, Carlino A, et al. Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. Gastrointest Endosc 2010;71:715–721.
82. Sohda M, Kuwano H. Current status and future prospects for esophageal
cancer treatment. Ann Thorac Cardiovasc Surg 2017;23:1–11.
83. Tanaka T, Ishiguro H, Kuwabara Y, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010;29:83.
84. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–39.
85. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: a global phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-IVBE). J Clin Oncol 2014;32(suppl 3):LBA7.
86. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717–726.
87. Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol 2018;36:61–67.
88. Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol 2019;37(suppl 4):abstr 2.
89. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
90. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455–2465.
91. Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol 2016;31:1141–1146.
92. Chang DT, Chapman C, Shen J, et al. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Am J Clin Oncol 2009;32:405–410.
93. Sepesi B, Watson TJ, Zhou D, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? (An analysis of esophagectomy specimens). J Am Coll Surg 2010;210:418–427.
94. Holscher AH, Bollschweiler E, Schroder W, et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011;254:802–808.
95. Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg 2013;257:1032–1038.
96. Conio M, Repici A, Battaglia G, et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007;102:2667–2677.
97. Madhusudhan C, Saluja SS, Pal S, et al. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus 2009;22:331–336.
98. Ahmed O, Bolger JC, O’Neill B, et al. Use of esophageal stents to relieve dysphagia during neoadjuvant therapy prior to esophageal resection: a systematic review. Dis Esophagus 2020;33:doz090.
99. Ligthart-Melis GC, Weijs PJ, te Boveldt ND, et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer. Dis Esophagus 2013;26:587–593.
100. Kim KR, Shin JH, Song HY, et al. Palliative treatment of malignant esophagopulmonary fistulas with covered expandable metallic stents. AJR Am J Roentgenol 2009;193:W278–W282.
101. Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76:1087–1094.
102. Kopacova M, Tacheci I, Rejchrt S, et al. Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol 2009;15:5397–5408.
103. Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 2013;31:4306–4310.
104. Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc 2011;74:610–624.
105. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.
106. Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc 2018;87:907–931.